Skip to main content
Altuviiio logo

HemAssistTM Sanofi Support


We complement the support you provide your ALTUVIIIO patients and their caregivers with access to treatment, education, and financial assistance from Sanofi.

Enroll your patients

Financial assistance

Every person’s situation is different, which is why we work directly with patients to help identify the financial assistance programs for which they may be eligible.

Treatment education

We can help your patients understand more about ALTUVIIIO, as well as offer supplemental administration training and tips to help them start and stay on track with treatment as prescribed.

Access to treatment

From navigating insurance coverage to assisting with reimbursement, our team works with you and your patients to get them started on ALTUVIIIO as efficiently as possible.

Financial assistance:

Copay Assistance Program*

HemAssist may be able to help eligible ALTUVIIIO patients gain access to treatment for as little as $0.

Free Trial Program

Patients prescribed ALTUVIIIO for the first time can receive their first 30-day supply of treatment generally within 24 to 48 hours with a valid prescription.

Patient Assistance Program

HemAssist’s Patient Assistance Program may be available to help eligible ALTUVIIIO patients who are uninsured, underinsured, or experiencing a temporary loss in insurance coverage.

* Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, state pharmaceutical assistance program, etc. to pay in part or in full for their ALTUVIIIO prescription. Not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Copay Program at any time without notice. Savings by patients may vary depending on their out-of-pocket costs. The program is intended to help patients afford their ALTUVIIIO prescription. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms.

† Claims for free products dispensed through the Free Trial or Patient Assistance Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

Field Reimbursement Managers (FRMs)

For you:

Our FRMs can help you navigate insurance coverage and provide reimbursement education and solutions.

Case Managers



For you:

Our dedicated Case Managers will provide you with personalized insurance investigations and answer your specific questions about financial assistance options for eligible patients.

 

For your patients:

Case Managers assist with navigating insurance coverage and identifying the financial support patients may be eligible for.

Clinical Educators (CEs)


For you:

CEs can answer questions about your patient’s condition and treatment and can provide helpful support, including disease state education, treatment tips, and supplemental administration training.

 

For your patients:

CEs are your patient’s point of contact for ALTUVIIIO education, tips, supplemental infusion training, and ongoing support.

Questions? Call 1-833-723-5463, Monday through Friday, 8 AM to 7 PM ET, or request a visit from an ALTUVIIIO Rep. They can connect you with a Case Manager, who can further explain what the ALTUVIIIO assistance programs can offer your patients.

Tools for your patients

Infusion Overview

Doctor Discussion Guide

ALTUVIIIO Patient Brochure: An Overview

Help patients connect with peers

Through the Peer Mentor Program, your patients can connect with a real ALTUVIIIO patient for advice, information about their experience, and more.

Request a Peer Mentor

Keep track of hemophilia with the MicroHealth app

Sanofi has joined with MicroHealth in supporting patients and healthcare providers to better manage hemophilia. MicroHealth is an app specifically designed to help patients with hemophilia track their treatment and progress and share this information with healthcare providers.

Download MicroHealth Brochure
Microhealth app
icon bubble

Ready to talk about ALTUVIIIO?

Set up time to talk with an ALTUVIIIO Representative to get to know ALTUVIIIO better.

icon finance

Resources for HCPs

Learn about resources and tools for your practice as well as billing and coding information for ALTUVIIIO.

Indication

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with Hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2025 Sanofi. All rights reserved. ALTUVIIIO, HemAssist, MyALTUVIIIO, and Sanofi are trademarks of Sanofi or an affiliate. MAT-US-2403562-v5.0-08/2025 Last Updated: August 2025